Plasmodium falciparum: Immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies

Experimental Parasitology

Volumn 115, Issue 4, 2007, Pages 403-408

  Nagata, Mark ^a   Wong, Teri ^b   Clements, David ^b   Hui, George ^a  

^a UNIVERSITY OF HAWAII   (United States)

^b Hawaii Biotech   (United States)

Author keywords

alkaline phosphatase; AP; Blocking antibodies; bovine serum albumin; BSA; C terminal 19 kDa fragment of MSP1; C terminal 42 kDa fragment of MSP1; CFA; Freund's complete adjuvant; Inhibitory antibodies; Malaria; Merozoite surface protein 1; merozoite surface protein 1; monophospholipid A; MPL; MSP1; MSP1 19; MSP1 42; Plasmodium falciparum; rabbit; Rbt; Vaccine

Indexed keywords

ANTISERUM; IMMUNOLOGICAL ADJUVANT; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 1-42; MONTANIDE ISA51; PROTEIN ANTIBODY; RC 529; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; INHIBITION KINETICS; NONHUMAN; PARASITE DEVELOPMENT; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; MEROZOITE SURFACE PROTEIN 1; PLASMODIUM FALCIPARUM; RABBITS;

BOVINAE; ORYCTOLAGUS CUNICULUS; PLASMODIUM FALCIPARUM;

EID: 33846707202     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2006.10.005     Document Type: Article

References (42)

1. Branch O.H., Udhayakumar V., Hightower A.W., Oloo A.J., Hawley W.A., Nahlen B.L., Bloland P.B., Kaslow D.C., and Lal A.A. A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. American Journal of Tropical Medicine and Hygiene 58 (1998) 211-219
2. Burns J.M., Daly T.M., Vaidya A.B., and Long C.A. The 3′ portion of the gene for a Plasmodium yoelii merozoite surface antigen encodes the epitope recognized by a protective monoclonal antibody. Proceedings of the National Academy of Sciences of the United States of America 85 (1988) 602-606
3. Burns J.M., Parke L.A., Daly T.M., Cavacini L.A., Weidanz W.P., and Long C.A. A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. Journal of Immunology 142 (1989) 2835-2840
4. Chang S.P., Gibson H.L., Lee-Ng C.T., Barr P.J., and Hui G.S. A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. Journal of Immunology 149 (1992) 548-555
5. Chang S.P., Nikaido C.M., Hashimoto A.C., Hashiro C.Q., Yokota B.T., and Hui G.S. Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype. Journal of Immunology 152 (1994) 3483-3490
6. Chang S.P., Case S.E., Gosnell W.L., Hashimoto A., Kramer K.J., Tam L.Q., Hashiro C.Q., Nikaido C.M., Gibson H.L., Lee-Ng C.T., Barr P.J., Yokota B.T., and Hut G.S. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infection and Immunity 64 (1996) 253-261
7. Chappel J.A., and Holder A.A. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Molecular and Biochemical Parasitology 60 (1993) 303-311
8. Darko C.A., Angov E., Collins W.E., Bergmann-Leitner E.S., Girouard A.S., Hitt S.L., McBride J.S., Diggs C.L., Holder A.A., Long C.A., Barnwell J.W., and Lyon J.A. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites. Infection and Immunity 73 (2005) 287-297
9. Egan A.F., Chappel J.A., Burghaus P.A., Morris J.S., McBride J.S., Holder A.A., Kaslow D.C., and Riley E.M. Serum antibodies from malaria-exposed people recognize conserved epitopes formed by the two epidermal growth factor motifs of MSP1(19), the carboxy-terminal fragment of the major merozoite surface protein of Plasmodium falciparum. Infection and Immunity 63 (1995) 456-466
10. Egan A.F., Morris J., Barnish G., Allen S., Greenwood B.M., Kaslow D.C., Holder A.A., and Riley E.M. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. Journal of Infectious Diseases 173 (1996) 765-769
11. Egan A.F., Burghaus P., Druilhe P., Holder A.A., and Riley E.M. Human antibodies to the 19 kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunology 21 (1999) 133-139
12. Guevara Patino J.A., Holder A.A., McBride J.S., and Blackman M.J. Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. Journal of Experimental Medicine 186 (1997) 1689-1699
13. Holder A.A., Guevara Patino J.A., Uthaipibull C., Syed S.E., Ling I.T., Scott-Finnigan T., and Blackman M.J. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. Parassitologia 41 (1999) 409-414
14. Hui G.S., and Chang S.P. Plasmodium falciparum: induction of biologically active antibodies to gp195 is dependent on the choice of adjuvants. Experimental Parasitology 75 (1992) 155-157
15. Hui G.S., and Hashimoto C.N. Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1. Infection and Immunity 66 (1998) 5329-5336
16. Hui G.S., and Siddiqui W.A. Serum from Pf195 protected Aotus monkeys inhibit Plasmodium falciparum growth in vitro. Experimental Parasitology 64 (1987) 519-522
17. Hui G.S., Chang S.P., Gibson H., Hashimoto A., Hashiro C., Barr P.J., and Kotani S. Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195. Journal of Immunology 147 (1991) 3935-3941
18. Hui G.S., Tam L.Q., Chang S.P., Case S.E., Hashiro C., Siddiqui W.A., Shiba T., Kusumoto S., and Kotani S. Synthetic low-toxicity muramyl dipeptide and monophosphoryl lipid A replace Freund complete adjuvant in inducing growth-inhibitory antibodies to the Plasmodium falciparum major merozoite surface protein, gp195. Infection and Immunity 59 (1991) 1585-1591
19. Hui G.S., Hashimoto A., and Chang S.P. Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum. Infection and Immunity 60 (1992) 1422-1433
20. Hui G.S., Hashiro C., Nikaido C., Case S.E., Hashimoto A., Gibson H., Barr P.J., and Chang S.P. Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus. Infection and Immunity 61 (1993) 3403-3411
21. Hui G.S., Gosnell W.L., Case S.E., Hashiro C., Nikaido C., Hashimoto A., and Kaslow D.C. Immunogenicity of the C-terminal 19-kDa fragment of the Plasmodium falciparum merozoite surface protein 1 (MSP1), YMSP1(19) expressed in S. cerevisiae. Journal of Immunology 153 (1994) 2544-2553
22. John C.C., O'Donnell R.A., Sumba P.O., Moormann A.M., Koning-Ward T.F., King C.L., Kazura J.W., and Crabb B.S. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. Journal of Immunology 173 (2004) 666-672
23. Kaslow D.C., Hui G., and Kumar S. Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Molecular and Biochemical Parasitology 63 (1994) 283-289
24. Keitel W.A., Kester K.E., Atmar R.L., White A.C., Bond N.H., Holland C.A., Krzych U., Palmer D.R., Egan A., Diggs C., Ballou W.R., Hall B.F., and Kaslow D. Phase I trial of two recombinant vaccines containing the 19 kDa carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18 (1999) 531-539
25. Koning-Ward T.F., O'Donnell R.A., Drew D.R., Thomson R., Speed T.P., and Crabb B.S. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. Journal of Experimental Medicine 198 (2003) 869-875
26. Kumar S., Yadava A., Keister D.B., Tian J.H., Ohl M., Perdue-Greenfield K.A., Miller L.H., and Kaslow D.C. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Molecular Medicine 1 (1995) 325-332
27. Ling I.T., Ogun S.A., and Holder A.A. The combined epidermal growth factor-like modules of Plasmodium yoelii merozoite surface protein-1 are required for a protective immune response to the parasite. Parasite Immunology 17 (1995) 425-433
28. Morgan W.D., Lock M.J., Frenkiel T.A., Grainger M., and Holder A.A. Malaria parasite-inhibitory antibody epitopes on Plasmodium falciparum merozoite surface protein-1(19) mapped by TROSY NMR. Molecular and Biochemical Parasitology 138 (2004) 29-36
29. Nwuba R.I., Sodeinde O., Anumudu C.I., Omosun Y.O., Odaibo A.B., Holder A.A., and Nwagwu M. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infection and Immunity 70 (2002) 5328-5331
30. O'Donnell R.A., Koning-Ward T.F., Burt R.A., Bockarie M., Reeder J.C., Cowman A.F., and Crabb B.S. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. Journal of Experimental Medicine 193 (2001) 1403-1412
31. Okech B.A., Corran P.H., Todd J., Joynson-Hicks A., Uthaipibull C., Egwang T.G., Holder A.A., and Riley E.M. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infection and Immunity 72 (2004) 1557-1567
32. Perraut R., Marrama L., Diouf B., Sokhna C., Tall A., Nabeth P., Trape J.F., Longacre S., and Mercereau-Puijalon O. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. Journal of Infectious Diseases 191 (2005) 264-271
33. Pichyangkul S., Gettayacamin M., Miller R.S., Lyon J.A., Angov E., Tongtawe P., Ruble D.L., Heppner Jr. D.G., Kester K.E., Ballou W.R., Diggs C.L., Voss G., Cohen J.D., and Walsh D.S. Pre-clinical evaluation of the malaria vaccine candidate Plasmodium falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22 (2004) 3831-3840
34. Sachdeva S., Mohmmed A., Dasaradhi P.V., Crabb B.S., Katyal A., Malhotra P., and Chauhan V.S. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants. Vaccine 24 (2006) 2007-2016
35. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., Martin L.B., Saul A.J., Miller L.H., and Long C.A. Immunity to Recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infection and Immunity 74 (2006) 4573-4580
36. Stowers A.W., Cioce V., Shimp R.L., Lawson M., Hui G., Muratova O., Kaslow D.C., Robinson R., Long C.A., and Miller L.H. Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infection and Immunity 69 (2001) 1536-1546
37. Stowers A.W., Chen Lh L.H., Zhang Y., Kennedy M.C., Zou L., Lambert L., Rice T.J., Kaslow D.C., Saul A., Long C.A., Meade H., and Miller L.H. A recombinant vaccine expressed in the milk of transgenic mice protects Aotus monkeys from a lethal challenge with Plasmodium falciparum. Proceedings of the National Academy of Sciences of the United States of America 99 (2002) 339-344
38. Tian J.H., Good M.F., Hirunpetcharat C., Kumar S., Ling I.T., Jackson D., Cooper J., Lukszo J., Coligan J., Ahlers J., Saul A., Berzofsky J.A., Holder A.A., Miller L.H., and Kaslow D.C. Definition of T cell epitopes within the 19 kDa carboxylterminal fragment of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) and their role in immunity to malaria. Parasite Immunology 20 (1998) 263-278
39. Uthaipibull C., Aufiero B., Syed S.E., Hansen B., Patino J.A., Angov E., Ling I.T., Fegeding K., Morgan W.D., Ockenhouse C., Birdsall B., Feeney J., Lyon J.A., and Holder A.A. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. Journal of Molecular Biology 307 (2001) 1381-1394
40. Vukovic P., Hogarth P.M., Barnes N., Kaslow D.C., and Good M.F. Immunoglobulin G3 antibodies specific for the 19-kilodalton carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein 1 transfer protection to mice deficient in Fc-gammaRI receptors. Infection and Immunity 68 (2000) 3019-3022
41. Vukovic P., Chen K., Qin Liu X., Foley M., Boyd A., Kaslow D., and Good M.F. Single-chain antibodies produced by phage display against the C-terminal 19 kDa region of merozoite surface protein-1 of Plasmodium yoelii reduce parasite growth following challenge. Vaccine 20 (2002) 2826-2835
42. Wipasa J., Xu H., Makobongo M., Gatton M., Stowers A., and Good M.F. Nature and specificity of the required protective immune response that develops postchallenge in mice vaccinated with the 19-kilodalton fragment of Plasmodium yoelii merozoite surface protein 1. Infection and Immunity 70 (2002) 6013-6020